AMSTERDAM, The Netherlands, August 18, 2010 /PRNewswire-FirstCall/ --
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of
human gene therapy, today announced that the Marketing Authorisation
Application (MAA) for Glybera(R) remains on schedule following meetings with
the E